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Objectives: The aim of this study was to describe the cohort of patients who have been treated with
Denosumab as neoadjuvant therapy prior to surgery for aggressive giant cell tumor of bone in the ex-
tremities, to evaluate the radiological responses to Denosumab comparing Choi criteria and a newly
described computerized tomography (CT) classification, and to evaluate the risk of local recurrence after
intralesional curettage or radical excision.
Methods: We retrospectively evaluated 36 patients (20 females and 16 males; mean age at diagnosis 36
years (range, 18e64)) treated with neoadjuvant Denosumab therapy prior to surgery for aggressive giant
cell tumor of bone in the extremities. The radiological responses to Denosumab treatment were analyzed
on the preoperative images after the neoadjuvant course with the Choi criteria and with a newly pro-
posed classification based on CT. All these images were independently reviewed by two of the re-
searchers. Surgical intervention methods were noted and local recurrence rates were evaluated. The
correlation between radiological response amount and local recurrence were analyzed for both Choi
criteria and the new CT classification.
Results: Denosumab was administered for a mean of 21 weeks (range 7e133). Five patients also had a
short postoperative course. According to Choi criteria there was a radiological response in 32 patients
(89%), while the new CT classification identified responses in all the 36 patients (100%). The identification
of changes after 7 weeks of treatment was higher using the CT classification compared to Choi criteria
(p ¼ 0.043 vs p ¼ 0.462). The surgical interventions after Denosumab comprised curettage in 29 patients
(74%) and resection in 7 (26%). Local recurrence was higher in patients managed with intralesional
curettage than in those treated with en bloc resection (55.1% vs 0%, p < 0.001). At last follow up 19
patients (53%) required en bloc resections. Good responders to Denosumab (type 2C) had lower risk of
local recurrence (p ¼ 0.047) after either resection or curettage.
Conclusion: The new CT classification evaluated more accurately the response to Denosumab. Our
experience suggests that the requirement for radical bone resection remains high despite the use of
Denosumab.
Level of evidence: Level IV, Therapeutic Study.
© 2019 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Via Pupilli 1, 40136 Bologna,
ri).
ciation of Orthopaedics and
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Giant-cell tumor of bone (GCTB) is a benign but aggressive
skeletal neoplasm that most commonly affects young adults. The
disease characteristically presents as a meta-epiphyseal, lytic lesion
and it is most often located in the distal femur, proximal tibia, and
distal radius.1 The cortex of the involved bone is usually thinned,
expanded, and sometimes breached with or without soft tissuervices by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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tumors is the high local recurrence (LR) rate (range 21e65%).2 Local
recurrence is influenced by several factors including age of the
patient, Campanacci grade, tumor location, soft tissue extension,
pathological fracture, the type of treatment performed. Moreover,
several molecular an genetic factors have been proposed as risk
factors for LR.3,4
Intralesional curettage, aims to preserve the bone structure but
it is unfortunately associated with higher risk of LR.5 Therefore,
several adjuvant treatments have been proposed to reduce the risk
of recurrence, including phenol, liquid nitrogen and poly-
methylmethacrylate cement.1 On the other hand, radical bone re-
sections with wide margins reduce LR rates, but they are associated
with increased morbidity and possible functional impairment.6
During the last decade, a monoclonal antibody that inhibits
RANKL called Denosumab has started to be considered as a new
option for the treatment of locally advanced GCTB. Some of the
mechanisms of action described are the suppression in the osteo-
clast differentiation, the increase of osteocalcin and the final dif-
ferentiation of stromal cells into osteoblasts.7 Denosumab
stimulate the reconstruction of a new peripheral osseous rim and
the progressive ossification of the lesion after its administration.
This effect switches the stage of the disease from aggressive to
active or latent. Denosumab may therefore allow conservative
surgery with bone and joint preserving surgery in patients with
large tumors that would have been treated with radical resections
in the past.8,9 Denosumab has been reported to result in beneficial
surgical downstaging10e12; however, the results were from patients
who remained on denosumab or inwhom it had been discontinued
but with a short follow-up.10e12
Even though Denosumab downstages the GCTB, concerns have
been raised for the reactivation of the disease after stopping the
treatment.13 Moreover, there are still some doubts on which is the
most appropriate surgery after Denosumab and the long-term re-
sults after intralesional curettage.14 Additionally, response to Deno-
sumab therapy is generally evaluated with classification originally
proposed to evaluate responses to chemotherapy in cancer, such as
MD Anderson criteria, RECIST criteria, modified EORTC criteria and
Choi criteria.11,15 Denosumab cannot make GCT disappear but it
makes the tumour calcify. Thus, it is not possible to have a “complete
response” to therapy as described in previous classifications.
The aim of this report is to describe the cohort of patients who
have been treated with Denosumab as neoadjuvant therapy and
evaluate the radiological responses. In addition, we evaluated if the
use of Denosumab can modify the evolution of the disease, the
development of LR, and whether or not it allows us to perform
conservative surgeries thereby maintaining the bone and joint
structure in the long-term.
Patients and methods
At our Institution, 63 patients have been treated with Denosu-
mab for aggressive Campanacci stage 2e3 GCTB from 2010 to 2016.
Adult patients (18 years) affected by Campanacci grade 2e3
GCTB with localization in the limbs, who underwent surgery after
Denosumab treatment were included. All cases were histologically
revised by experienced pathologist at our Institution.
Patients who received Denosumab to treat lung metastasis at
diagnosis, patients who received Denosumab as a definitive treat-
ment without any surgery and those included in the initial trials
were excluded.10,16 Also, patients who had known or suspected
diagnosis of sarcoma, diagnosis of second malignancy within 5
years, who were lost to follow-up, who had incomplete medical
records and who died for other reasons during treatment were
excluded from the study.We identified a total of 36 patients who received Denosumab as
neoadjuvant therapy to surgery which were included in this
retrospective analysis. All the procedures followed were in accor-
dance with the ethical standards of the responsible committee on
human experimentation and with the Helsinki Declaration of 1975,
as revised in 2000. The independent ethics committee of our
Institution (Istituto Ortopedico Rizzoli, Bologna) approved the
study (File number: 0006276).
Denosumab (Xgeva® 120 mg) was given as a subcutaneous in-
jection every 4 weeks (with loading doses on day 8 and 15 in cycle
1). Planned duration of neoadjuvant denosumabwas 6e12months,
and the duration of adjuvant (postoperative) treatment was 6
months.
All patients underwent a routine dental exam before starting
treatment, and were advised to take daily supplements containing
500e1000 mg calcium and 400e800 IU vitamin D.
Intralesional surgery (curettage) consisted of intralesional
curettage, additional high-speed burring, followed by filling of the
defect with cementing. No adjuvant intraoperative treatments
were used.
Radical surgery was defined as a wide resectionwith or without
reconstruction. The surgical procedures after Denosumab admin-
istration were considered initial surgery for analytical purposes.
The response to Denosumab treatment was evaluated on the
preoperative images after the neoadjuvant course. All these images
were independently reviewed by two of the researchers (AS, RM).
The radiological responses to Denosumab were analyzed with the
Choi criteria17 (Table 1) and with a newly proposed classification
based on computerized tomography (CT) (see Fig. 1).
Choi criteria were evaluated according to themodifications both
in size on different planes and in density (calcification) of the
tumour on CT scan.
According to the new ct classification, a progression of the dis-
ease (Type 0 response) was defined when an increase  25% of the
tumour was observed. We defined Stable disease (Type 1) those
cases with an increase < 25% of GCT. Partial response (Type 2) was
defined as a GCT stable in size and with ossification of the shell. It
was sub classified according to the percentage of internal ossifica-
tion (Type 2A: <30%; Type 2B: 30e60%; Type 2C: >60%).
The newly CTclassification cut-offs were decided arbitrarily, and
verified according to our data (Table 2).
At latest follow-up patients were functionally evaluated with
the Musculoskeletal Tumor Society (MSTS) score.18 Moreover, the
presence of arthritis was evaluated according to the
KellgreneLawrence classification on the last x-rays available and
was considered positive when grades 2 (space narrowing), 3
(osteophytes) or 4 (bone deformity) were observed.19
Patients' characteristics are presented by frequencies and per-
centages for categorical variables, mean and range for continuous
variables.
The differences between groups were compared by
ManneWhitney U test. Significance was set with P values < 0.05 in
all statistical analyses, which were completed using the Statistical
Package for Social Science (IBM Corp. Released 2013. IBM SPSS
Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.).
Results
In the cohort, there were 20 females (56%) and 16 males (44%).
The mean age at diagnosis was 36 years (range, 18e64). Based on
initial imaging, 25 (69%) tumors were classified as Campanacci
grade 3 and 11 (31%) as Campanacci grade 2. Seventeen GCTB were
located in the lower limb (6 in the distal femur, 8 in the proximal
tibia, and three in the distal tibia), 19 in the upper limb (12 in the




Complete response (CR) Disappearance of all lesions
Partial response (PR) A decrease in size of 10% or a decrease in tumour density 15%
Stable disease (SD) Does not meet the criteria for CR, PR or PD.
Progression of disease (PD) An increase in tumour size of 10%
Fig. 1. Computerized tomography (CT) classification to asses GCTB changes after
Denosumab. On the left axial CT showing tumour at diagnosis, on the right after
Denosumab treatment. A) Type 2A response: Same size, ossification of the shell and
internal ossification <30%; B) Type 2B response: Same size, ossification of the shell and
internal ossification 30e60%; C) Type 2C response: Reduce size, ossification of the shell
and internal ossification >60%.
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diagnosed primary GCTB while 7 (19%) received it for locally
recurrent GCTB.
Patients had surgery after a mean of 21 weeks of treatment
(range 7e133). One patient (large, grade 3, distal radius GCT)
received pre-operative course of Denosumab for 133 weeks as she
originally refused surgery. Finally, she decided to go for surgeryTable 2






2C(resection and wrist arthrodesis) as she would like to become
pregnant.
Five patients also had a postoperative adjuvant course of
Denosumab for a mean of 23 weeks (range, 22e29 weeks).
Radiological response
According to Choi criteria, 4 patients were classified as stable
disease and 32 presented a partial response before the surgical
treatment. No correlation was observed between the length of the
treatment and changes in the radiological response using Choi
criteria (p ¼ 0.462).
With the newly proposed CT classification, 8 patients presented
a 2A response to Denosumab, 9 type 2B and 19 type 2C before the
surgical intervention.
Both observer were concordant in the evaluation using the CT
classification in 32 out of 36 cases with an inter observer reliability
of 88.9%. In details, three out of 4 discordant cases were between
type 2B and 2C and one between 2A and 2B.
Maximal response to Denosumab was observed in 33 out of 36
patients after 3 months of treatment. After that period, radiological
response maintained a plateau.
Interventions and complications
The surgical treatments after Denosumab included curettage in
29 (81%) patients and resection in 7 (19%) patients. The type of
treatment was chosen independently to the radiological response
either with the Choi criteria (p ¼ 0.546) or the CT classification
(p ¼ 0.451). The decision in terms of type of treatment was mainly
affected by the location, intraarticular compromise and soft tissue
extension.
Five (13%) patients presented complications related to Deno-
sumab administration. Two patients developed hypocalcemia, two
patients developed diffuse bone pain, and one patient presented a
stress fracture in a different bone. The treatment had to be stopped
at an early stage only in one of the patients presenting pain. The
other complications were managed without further impact on the
overall treatment.
Local recurrence
Mean follow-up was 35 months (range, 13e73 months).
The overall local recurrence rate was 16.7% (6 out of 36 patients)
and the mean time to develop it was 17 months (range, 5e22
months). According to the presentation, a slightly higher but notponse to Denosumab treatment.
Description
Increase 25% size of measurable lesions
<25% increase size of measurable lesions
Same size, ossification of the shell and internal ossification <30%
Same size, ossification of the shell and internal ossification 30e60%
Reduce size, ossification of the shell and internal ossification >60%
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compared with those presenting with recurrent GCTB (21% vs 13%,
p ¼ 0.457).
Based on the initial surgical treatment, 16 out of 29 patients
managed with intralesional curettage presented LR while no re-
currences were observed in those treated with en bloc resection
(55.1% vs 0%, p < 0.001). The treatments for LRs included: conver-
sion to endoprosthetic replacement in 5 patients, second curettage
in 10 patients and long term Denosumab therapy in the other one
patient.
Patients that presented radiological responses type 2C pre-
sented lower rates of local recurrence compared to all the other
type of responses (p ¼ 0.047). Nevertheless, no correlation was
observed between the radiological responses and local recurrence
when the Choi criteria were used (p ¼ 0.284).
Final results
Excluding 5 patients who underwent resection for LR in the
curettage group, radiographic signs of arthritis (Kellgren Lawrence
Classification grades 2, 3 and 4) were observed in 7 out of the 24
patients (33%) that were treated with intralesional curettage after a
mean of 23 months (range, 11e45) from initial surgery. All those
patients were converted to en-bloc resections in the long term. At
final follow up, the mean MSTS score did not differ between the
group of patients initially treated with curettage (mean 23, range
22e29) and the radical treatment group (mean 22, range 17e29)
(p ¼ 0.674).
The final surgical procedures were intralesional curettage in 17
patients (47%) and en-bloc resections in 19 patients (53%).
Comparing the initial and final procedures, 41% of the patients
initially treated with intralesional curettage (12 out of 29) were
converted to en-bloc resections either for local recurrence (5 pa-
tients) or arthritis (7 patients), while patients treated with re-
sections had similar MSTS scores without instances of recurrence.
Discussion
The exact use of Denosumab in patients with Giant Cell Tumors
of Bone is still a matter of controversy in orthopedic oncology. In
patients with advanced or locally aggressive disease, the proposed
benefit of Denosumab is to downstage the tumors, thereby allow-
ing a more conservative surgery. Most of the published series have
reported on the use of Denosumab for GCTB involving both axial
and appendicular bones.16,20 However, since surgery in centrally
located GCTB has higher risks, with significant morbidity and
important functional losses with respect to the extremities, the
indications for the use of Denosumab may differ according to the
location.
Another problem in the treatment with Denosumab is the lack
of reliability between the clinical and radiological responses after
the treatment. In most of the published series, Denosumab is
shown to be clinically effective in GCTB16,21,22; however, the
radiological outcome is generally evaluated using classifications
that were set up to identify therapeutic responses in solid tu-
mors.17,23 These classifications do not consider the increase in the
consolidation of the peripheral osseous rim and are more focused
on the reduction in size which create difficulties in the determi-
nation of the actual response to Denosumab and therefore in the
choice of the best treatment after the therapy.
Considering those problems, we described a new classification
based on CT to assess bone changes after Denosumab in GCTB and
then we compared that to Choi criteria.
We observed that the CT evaluation showed a better correlation
with the radiological responses and higher sensitivity in theevaluation of the responses than Choi. Additionally, we observed a
correlation between good radiological responses and lower local
recurrence rates, which suggest that the evaluation of the radio-
logical responses should be better characterized in order to identify
higher-risk patients.
Most of the local recurrences observed in our cohort occurred
after approximately 18 months after Denosumab stoppage, and the
risk of local recurrence appeared to be mainly influenced by the
type of initial surgical treatment performed. Traub et al22 already
addressed this issue, but also reported good outcomes after
Denosumab in conservatively treated GCTB. From our experience
GCTB densely ossify following Denosumab treatment and there-
fore, curettage may be insufficient to remove the tumor
completely.14,21 In this series, intralesional curettagewas associated
with a higher rate of LR and a significant percentage of patients
with X-rays signs of arthritis in the medium-term. Therefore, a very
high number of patients required en-bloc resections as a final
procedure.
For this reason, patients with severe articular compromise or
deformity may benefit from Denosumab to consolidate the tumor,
in order to perform en-bloc resection as first surgery. On the other
hand, patients with a reasonable bone stock can have curettage and
cementation or bone grafting after Denosumab in the attempt to
preserve the joint. Nevertheless, the surgeon and patient have to be
aware of the higher recurrence rate and possible development of
arthritis when curettage is performed compared to resection.
The complications related to Denosumab in this series were
similar to those reported in previous studies,10,16 and most of them
were managed without impact in the overall treatment. On the
other hand, most of the responses to Denosumab were seen after
approximately 5 months of treatment. We therefore feel that for
patients with tumors compromising the articular surface, a short
course of Denosumab (3e6 months) followed by wide resection
will provide a safer outcome with fewer local recurrences and
fewer side effects. On the other hand, if the joint surface is not
involved and there are no deformities, Denosumab in a short course
of 3 months followed by curettage might be advisable. Neverthe-
less, the surgeon has to be aware of the higher recurrence rate and
possible development of arthritis. In addition to that, the follow-up
in Denosumab patients, in particular in those treated with curet-
tage, should be more detailed for at least two years after the end of
the therapy, as recurrences might be seen later.
One of the limitations of this study is the retrospective analysis
of the data, which might induce information bias. In addition, since
the number of patients is small, we cannot draw any definitive
conclusions regarding the differences in recurrence rates and
complications between intralesional surgery and wide resection.
Another weakness of this study is the relatively short follow up
after Denosumab stoppage, which limits us to rule out possible
relapses in the long term. In addition, no comparison was possible
between the radiological results and pathological healing criteria.24
In addition, the study population is heterogeneous, as 11 large and
grade 2 GCT with involvement of the subchondral bone received
Denosumab, even though it is now well known that grade 2 Cam-
panacci GCT can be managed without neoadjuvant course of
Denosumab, This was due to the size and site of the tumors, in
order to downstage these tumours. Moreover, pre-operative MSTS
scores are lacking.
Due to that, the conclusions observed cannot be generalized.
Additionally, we cannot evaluate any differences in the behavior of
GCTB when Denosumab is administered for the primary tumor,
compared to its use in patients presenting with locally recurrent
GCTB. However, this is a mono-institutional series with all patients
operated by two senior surgeons. This cohort describes accurately
most of the current indications for the use of Denosumab in GCTB
L. Campanacci et al. / Acta Orthopaedica et Traumatologica Turcica 53 (2019) 376e380380located in the extremities, and to the extent of our knowledge this
is the only series based only on patients with GCTB located in
appendicular bones.
Conclusions
The radiological classification based on CT images may be more
accurate than Choi criteria in identifying more clearly early changes
due to Denosumab therapy.
Most of the patients can be treated surgically when GCT is
located in the extremities, and the use of Denosumab in short
course seems to be appropriate. Surgery should be performed
whenever possible and resection should be preferred in aggressive
GCTB with articular compromise.
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